$LIVN

LivaNova (NASDAQ: LIVN) officer to sell 1,650 shares

LivaNova PLC (LIVN) officer Francesco Bianchi plans to sell 1,650 shares of common stock under Rule 144, valued at $131,538. The shares stem from vested restricted stock units awarded in 2023 and 2024. Bianchi also sold 1,800 shares in May 2026 and 1,200 shares in June 2026.

Original reporting
Published Aug 31, 2026, 8:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 4:44 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$LIVN
Bearish
medium confidence
Mentioned
$LIVN
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$LIVNBearishLow
01

Why it matters

A modest insider sale may cause short‑term price softness but is unlikely to alter long‑term outlook.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Recent prior sales by the same officer and overall insider ownership levels could mitigate any negative perception.

Relevance 4/10Novelty 4/10Timing: today

Background

Form 144 filings disclose planned insider sales under Rule 144, signaling potential new share supply.

Company-level read

Ticker impact

$LIVNBearishMedium confidence
Context

Officer Francesco Bianchi filed a Form 144 to sell 1,650 shares worth $131,538, adding supply to the market.

Expected impact

Potential short-term dip of 0.5‑1% as the market digests the new supply.

Evidence & confidence

The sale size is small relative to total shares outstanding, but insider sales are often viewed as a bearish signal.

Market effects

Minimal; the sale does not affect the broader medical device sector.

Limited to U.S. investors holding LIVN.

Low; no cross‑border or macro implications.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals, so price impact may be negligible.

Key entities

  • Francesco Bianchi

    LivaNova officer filing the sale.

Related articles

$LIVNMedAI 8/10

LivaNova (LIVN) Q2 2026 Earnings Call Transcript

LivaNova (LIVN) reported Q2 2026 revenue of $390.6 million, up 10.8% reported and 9.8% constant currency, and adjusted diluted EPS of $1.26. Adjusted gross margin rose to 71.0%. Full-year 2026 revenue guidance was raised to 8% to 9% constant-currency growth, and adjusted EPS to $4.30 to $4.40, while free cash flow guidance was lowered to $140 million to $160 million.

$LIVNMedAI 8/10

LivaNova PLC Q2 2026 Earnings Call Summary

LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.

$LIVNHighAI 9/10

LivaNova Q2 Earnings Call Highlights

LivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.

$LIVNHighAI 9/10

LivaNova PLC: LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LivaNova PLC (Nasdaq: LIVN) reported Q2 2026 revenue of $390.6M, up 10.8% reported and 9.8% constant currency. Adjusted diluted EPS was $1.26. It raised full-year 2026 revenue guidance to 8% to 9% constant currency and adjusted diluted EPS to $4.30 to $4.40. It also signed a long-term supply agreement with Thermo Fisher for oxygenator components.

$LIVNHighAI 9/10

Why is LivaNova stock climbing today?

LivaNova shares rose 1.3% in after-hours to $86.42 after the company reported Q2 2026 results. Adjusted EPS was $1.26 vs $1.09 expected, and revenue was $390.6M vs $380.57M. LivaNova raised full-year 2026 adjusted diluted EPS guidance to $4.30-$4.40 (midpoint $4.35). KeyBanc lifted its price target to $92 from $83.

$LIVNHigh

LivaNova PLC (LIVN): Results of Operations and Financial Condition

LivaNova PLC (LIVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance – Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8% – Raised full-year 2026 revenue and adj